• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Authors » Marie Powers

Marie Powers

Articles

ARTICLES

'Disruptive science' lures Celgene to Lycera immune modulator deal

June 10, 2015
By Marie Powers
Privately held Lycera Corp. attracted its second major partner – and a potential buyer – in an exclusive global collaboration with Celgene Corp. focused on advancing Lycera's preclinical RORgamma agonists for cancer immunotherapy and a clinical-stage candidate, LYC-30937, in development for IBD.
Read More

Celtaxsys corrals investors, Cystic Fibrosis Foundation to fund phase II trial

June 9, 2015
By Marie Powers
Celtaxsys Inc. corralled a stable of investors, led by Domain Partners, to complete a $40 million series D round that was supplemented by an additional $5 million grant from Cystic Fibrosis (CF) Foundation Therapeutics, the nonprofit drug discovery and development affiliate of the Cystic Fibrosis Foundation (CFF).
Read More

Hope seen for type 1 diabetes fix, but obesity clouds type 2 outlook

June 5, 2015
By Marie Powers
Before the curtains even closed on the 2015 American Society of Clinical Oncology annual meeting, attention is turning to the American Diabetes Association's (ADA) 75th Scientific Sessions, which begin Friday in Boston. Abstract titles suggest presentations will address not only the raft of current drug development efforts and large cardiovascular outcome trials (CVOT) that have weighed on biopharmas in the diabetes space but also some of the emerging technologies to treat the disease.
Read More

Midatech starts building commercial framework with 'bolt-on' Dara buy

June 5, 2015
By Marie Powers
Midatech Pharma plc swung away from its core nanomedicine platform technology but picked up a toehold in North America and the scaffold of a commercial infrastructure by inking an agreement to acquire Dara Biosciences Inc.
Read More

Abbvie 'Enhanzes' Halozyme Therapeutics coffers in potential $1.193B collaboration

June 4, 2015
By Marie Powers

Fresh off reporting good news at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, Halozyme Therapeutics Inc. segued into yet another global collaboration and license agreement – this time with Abbvie Inc. – that could add $1.193 billion to its coffers.


Read More

Astellas first taker for Anokion's immune tolerance technology in potential $760M deal

June 3, 2015
By Cormac Sheridan and Marie Powers
Anokion SA is spinning out a new start-up, Kanyos Bio Inc., to serve as the vehicle for a development alliance in autoimmune disease with Astellas Pharma Inc., which could be worth up to $760 million in R&D funding, option exercise payments and milestones.
Read More

Neurovive walks the tightrope after its Ciclomulsion CIRCUS miss

June 2, 2015
By Marie Powers
Neurovive Pharmaceutical AB was dangling from the high wire after reporting a top-line analysis of the phase III CIRCUS study of Ciclomulsion, which indicated the study missed the primary clinical endpoint in patients with ST-segment elevation acute myocardial infarction (STEMI).
Read More

No red 'Heron' as Sustol proves 'MAGIC' in phase III

June 1, 2015
By Marie Powers
Investors in Heron Therapeutics Inc. received the good news they were awaiting when the phase III MAGIC study of Sustol (granisetron injection, extended release) hit its primary endpoint as part of a three-drug regimen together with the intravenous (I.V.) neurokinin-1 (NK1) receptor antagonist fosaprepitant and the I.V. corticosteroid dexamethasone to prevent delayed-onset chemotherapy-induced nausea and vomiting (CINV) following administration of highly emetogenic chemotherapy (HEC) agents.
Read More

Actavis, Valeant win on labels in IBS-D nods

May 29, 2015
By Marie Powers
The FDA's approval of Viberzi (eluxadoline) and the label extension for Xifaxan (rifaximin), both to treat irritable bowel syndrome with diarrhea (IBS-D) in adults, offered additional validation for the M&A approach of specialty pharmas Actavis plc and Valeant Pharmaceuticals International Inc.
Read More

Amgen axes brodalumab development; Astrazeneca keeps mum on next steps

May 27, 2015
By Marie Powers
After Friday's market close, while much of the U.S. had already turned its attention to the long Memorial Day weekend, Amgen Inc. quietly axed its stake in brodalumab, the much-heralded IL-17 inhibitor that was part of a co-development and commercialization deal with partner Astrazeneca plc.
Read More
View All Articles by Marie Powers

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 9, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for May 9, 2025.
  • US flag, stock market chart, White House

    100 days of uncertainty

    BioWorld
    The first 100 days of the Trump administration have been nothing short of chaotic, both in the U.S. and throughout the world. Shining a light through the...
  • AI generated, 3D rendering of protein degradation

    AACR 2025: Induced proximity strategy, beyond degraders

    BioWorld
    Targeted protein degradation has yet to notch its first approval. But with more than two dozen agents now in clinical trials, the strategy’s ultimate clinical...
  • NME Digest: Q1 2025

    BioWorld
    A quarterly dynamic table featuring new molecular entities (NMEs) revealed for the first time in current literature, at congresses and in company communications...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe